Clinical Trial Update: Improving Treatment of Inflammatory Bowel Diseases Through Better Understanding Infliximab Drug and Antibody Levels

View source ↗

Summary

A clinical trial investigating infliximab levels and anti-drug antibodies in Crohn's disease and ulcerative colitis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ul Ulcerative Colitis

Drugs mentioned

• Remicade (infliximab)

Snippet

Sponsor: University of Western Ontario, Canada | Conditions: Crohn's Disease, Ulcerative Colitis | Status: WITHDRAWN